Nature Communications (Jul 2022)

Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines

  • Li Wang,
  • Markus H. Kainulainen,
  • Nannan Jiang,
  • Han Di,
  • Gaston Bonenfant,
  • Lisa Mills,
  • Michael Currier,
  • Punya Shrivastava-Ranjan,
  • Brenda M. Calderon,
  • Mili Sheth,
  • Brian R. Mann,
  • Jaber Hossain,
  • Xudong Lin,
  • Sandra Lester,
  • Elizabeth A. Pusch,
  • Joyce Jones,
  • Dan Cui,
  • Payel Chatterjee,
  • M. Harley Jenks,
  • Esther K. Morantz,
  • Gloria P. Larson,
  • Masato Hatta,
  • Jennifer L. Harcourt,
  • Azaibi Tamin,
  • Yan Li,
  • Ying Tao,
  • Kun Zhao,
  • Kristine Lacek,
  • Ashley Burroughs,
  • Wei Wang,
  • Malania Wilson,
  • Terianne Wong,
  • So Hee Park,
  • Suxiang Tong,
  • John R. Barnes,
  • Mark W. Tenforde,
  • Wesley H. Self,
  • Nathan I. Shapiro,
  • Matthew C. Exline,
  • D. Clark Files,
  • Kevin W. Gibbs,
  • David N. Hager,
  • Manish Patel,
  • Alison L. Halpin,
  • Laura K. McMullan,
  • Justin S. Lee,
  • Hongjie Xia,
  • Xuping Xie,
  • Pei-Yong Shi,
  • C. Todd Davis,
  • Christina F. Spiropoulou,
  • Natalie J. Thornburg,
  • M. Steven Oberste,
  • Vivien G. Dugan,
  • SSEV Bioinformatics Working Group,
  • David E. Wentworth,
  • Bin Zhou

DOI
https://doi.org/10.1038/s41467-022-31929-6
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Emerging SARS-CoV-2 variants raise concerns on immune evasion. Here, the authors evaluate the neutralization efficiency of COVID-19 mRNA vaccinee sera against representative viruses of 13 WHO-designated SARS-CoV-2 variants of concern/interest.